Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 2, 2021- Phase 2 study sponsored by investigators at Universität Leipzig in Germany -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the initiation of a Phase 2...
-
Jan 14, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
-
Jan 8, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent...
-
Jan 5, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
-
Dec 14, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the closing of its underwritten public...
-
Dec 9, 2020
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering...
-
Dec 8, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced its intention to offer and sell shares of its...
-
Dec 8, 2020- Reduction of marrow blasts observed in all evaluable patients -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive preliminary data from its ongoing...
-
Dec 7, 2020- Tumor reductions observed in 6 of 7 patients treated at 300 mg BID following median 4 prior lines of therapy -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated data from its ongoing Phase 1,...
-
Dec 2, 2020- KOL Event featuring Dr. Amit Verma scheduled for Tuesday, December 8 at 8:00 a.m. ET -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a virtual KOL event on...